Mucosal 2-DG Dispenser With Acidic pH for Mucus Penetration

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing formulations of 2-deoxy-glucose (2-DG) and its analogues for mucosal administration suffer from reduced bioavailability due to interaction with free amines in mucus, particularly in thick mucus conditions, leading to ineffective delivery and efficacy.

Innovation Solution

Formulating the pharmaceutical composition with a pH lower than 7.4, preferably between 3.0 and 7.0, and incorporating a buffering agent such as citrate, phosphate, or acetate to maintain this acidic pH, thereby reducing imine formation and enhancing mucus penetration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If 2-DG is administered mucosally in conventional formulations, then it interacts with free amines in mucus to form imines, but this reduces bioavailability and efficacy

Engineering Contradiction:
ImprovebioavailabilityVSAvoidimine formation
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the pH parameter of the pharmaceutical composition to be lower than 7.4 (preferably 6.8-7.2), which suppresses the formation of imines between 2-DG and free amines in mucus, thereby improving bioavailability and reducing harmful interactions

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces a buffering agent as an intermediary substance that maintains the pH of the composition below 7.4, preventing direct harmful interaction between 2-DG and mucus amines while ensuring stable drug delivery

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If the pH is reduced to prevent imine formation, then bioavailability increases, but formulation stability and safety must be maintained

Engineering Contradiction:
ImprovebioavailabilityVSAvoidformulation stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent optimizes the pH parameter to a specific range (6.8-7.2) that balances multiple requirements: low enough to suppress imine formation and improve bioavailability, but high enough to maintain formulation stability and safety for mucosal administration

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The buffering agent acts as a mediator that stabilizes the pH within the optimal range, preventing both excessive acidity that could harm mucosal tissues and insufficient acidity that would allow imine formation, thus ensuring formulation stability

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The acidic pH formulation significantly increases the bioavailability of 2-DG and its analogues, improving their efficacy in treating respiratory infections by enhancing penetration through mucosal barriers.

Implementation Method 1

the 2-DG and analogues interacted with free amines in the mucus, leading to the formation of Schiff's bases (imines)

Methodology Applied
Scientific EffectImine formation: Chemical Bonding

Implementation Method 2

reducing the pH of the formulation improved mucus penetration, thereby increasing bioavailability

Methodology Applied
Scientific EffectpH-dependent penetration:

Data Source

PatentEP4582080A1Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof
Publication Date: 2025.07.09 G ST ANTIVIRALS GMBH
  • EP4582080A1 patent drawingFigure 1~2
  • EP4582080A1 patent drawingFigure 3~4
  • EP4582080A1 patent drawingFigure 5~6

AI summary

Disclosed is a pharmaceutical dispenser for mucosal administration, preferably intranasal or inhalatory administration, containing a pharmaceutical composition. The pharmaceutical composition comprises an active pharmaceutical ingredient (API) selected from the group consisting of 2-deoxy-glucose (2-DG) and analogues thereof, or a pharmaceutically acceptable salt of the API. The pH of the pharmaceutical composition is lower than 7.4, optionally upon reconstitution in water. Also disclosed is a method for mucosally administering this pharmaceutical composition, preferably for preventing or treating an infection.